Viewpoints

New studies reveal the promise and feasibility of transdermal vaccine delivery.

Quality management requires more effort in a complex supply chain.

Supplier differentiation is increasingly important in the highly competitive arena of pharmaceutical outsourcing.

Croatia is on track to join the EU in 2013 and offers a well-developed pharmaceutical market. However, its EU membership application has undergone much scrutiny.

There have been several new stories and reports lately that paint a rather gloomy picture of the state of pharma R&D.

Getting an answer is easy-asking the right question is apparently more difficult.

A new report places pharmaceutical and healthcare companies ahead in corporate and social governance.

US support of regenerative medicine is essential for maintaining a lead on healthcare innovation.

Which route will we take to arrive at a national stem-cell policy?

Switzerland is an important power in Europe's pharmaceutical industry.

One of the perks of my job is that I can travel to previously unvisited cities. This month, I was lucky enough to be in Switzerland.

Can microdosing make medicines safer and more effective for children?

Sometimes, there are just too many cooks in the kitchen.

FDA weighs multiple views regarding the Biologics Price Competition and Innovation Act.

This month's BIO Convention will encourage needed conversations.

The greatest challenge faced by the EMA is the continuing expansion of the EU.

It was a mixed crowd hosted by Dusseldorf in the middle of May.

As I strolled through Times Square, famous brand coffee cup in hand, towards the Jacob K. Javits Convention Center in New York, my thoughts were entirely focused on Interphex.

Those who doubt there's faith in science, should check out our annual Bioprocessing Survey.

Can the semiconductor industry help Big Pharma develop therapies?

India has the potential to become the new star of the biotechnology industry.

Many factors affect research results.

Despite initiatives to encourage multinational pharma companies to conduct R&D in the UK, the country may be losing its edge; is Pfizer's decision to exit a key site earlier this year the beginning of a mass exodus?

Research and development may be headed for divorce.

PhRMA efforts of industry's R&D scientists.

In any industry, inspections can be a pain, and pharma is no exception.

The need for greater process understanding raises the bar for suppliers.

Having spent the last five years of my life in Tokyo, I wanted to start this month's Editor's comment by offering my very deepest sympathy to all those who have been affected by the earthquake and tsunami in Japan.

Europe's approach to pharmacovigilance has room for improvement that European agencies are working on.

In France, public confidence in health authorities and pharmaceutical industry has been shaken by a safety scandal over the drug Mediator (benfluorex hydrochloride).